Cyclophosphamide News and Research

RSS

Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.

Breakthroughs in hematopoietic cell transplantation to be presented at 53rd ASH meeting

Hematopoietic cell transplantation (HCT), the transplantation of blood-forming stem cells from the bone marrow, peripheral blood, or umbilical cord blood, is the primary option for treatment for many patients who suffer from various hematologic disorders, including blood cancers, sickle cell disease, bone marrow deficiencies, bleeding disorders, and autoimmune disorders. Research investigating breakthroughs in hematopoietic cell transplantation will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

Memgen to present ISF35 clinical trial data on CLL at 53rd ASH meeting

Memgen, LLC announces the following abstract on ISF35, the Company's lead product, will be presented during the 53rd Annual Meeting of the American Society of Hematology (ASH) in San Diego, CA.

12 Dec 2011

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced results from CLEOPATRA, the first randomized Phase III study of the investigational HER2-targeted medicine pertuzumab.

8 Dec 2011

ZIOPHARM receives European patent allowance for palifosfamide to treat cancer

ZIOPHARM Oncology, Inc. announced today that it has received an allowance from the European Patent Office for Patent Application No. 05 821 125.1, entitled "Salts of Isophosphoramide mustard and analogs thereof as anti-tumor agents" with claims directed to pharmaceutical compositions of a novel DNA cross-linker, including palifosfamide and their use in treating cancer.

7 Dec 2011

Genentech announces results from pertuzumab studies on HER2-positive breast cancer

Genentech, a member of the Roche Group, today announced the company will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium December 6-10.

30 Nov 2011

PLoS ONE publishes study on darinaparsin, a multivalent chemotherapeutic

ZIOPHARM Oncology, Inc. announced today the publication of a darinaparsin (Zinapar or ZIO-101) study in the PLoS ONE, an international, peer-reviewed, open-access, online publication of the Public Library of Science.

21 Nov 2011

Mycophenolate mofetil superior to azathioprine for lupus nephritis

A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis.

17 Nov 2011

ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies of darinaparsin, a novel organic arsenic, in various solid tumor models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

16 Nov 2011

ZIOPHARM announces darinaparsin preclinical data on prostate cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that results from preclinical studies of darinaparsin (Zinapar or ZIO-101), a novel organic arsenic, in prostate cancer were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

14 Nov 2011

Human Genome Sciences to present abstracts regarding BENLYSTA, SLE at ACR/ARHP meeting

Human Genome Sciences, Inc. announced today that several abstracts related to BENLYSTA (belimumab) and systemic lupus erythematosus will be presented at the annual meeting of the American College of Rheumatology/ Association of Rheumatology Health Professionals, being held in Chicago, IL from November 4 to November 9, 2011.

5 Nov 2011

Allos third quarter net loss decreases to $11.2 million

Allos Therapeutics, Inc. today reported financial results for the three months ended September 30, 2011.

3 Nov 2011

ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma model

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide in a pediatric sarcoma model.

29 Oct 2011

ChemoCentryx commences CCX168 Phase II trial in ANCA-associated vasculitis

ChemoCentryx, Inc., today announced the initiation of a Phase II clinical trial for CCX168, an orally-administered small molecule for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a disease which can lead to renal and pulmonary failure.

18 Oct 2011

Merrimack begins MM-121 Phase 2 combination trial in HER2-negative breast cancer

Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, combined with paclitaxel in the neoadjuvant setting of HER2-negative breast cancer patients.

12 Oct 2011

Aduro initiates CRS-207 and GVAX Pancreas Cancer Vaccine Phase 2 clinical trial

Aduro BioTech, Inc. announces the treatment of the first patient in the Phase 2 pancreatic cancer clinical trial of the sequential administration of two cancer vaccines: Aduro's CRS-207 and GVAX Pancreas Cancer Vaccine.

11 Oct 2011

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced the results of the Phase II study TDM4450g in people with previously untreated HER2-positive metastatic breast cancer.

26 Sep 2011

FDA grants Orphan Drug Designation for Accentia's Revimmune to prevent GVHD

Accentia Biopharmaceuticals, Inc. and its majority-owned subsidiary, Biovest International, Inc., today jointly announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Revimmune, the Company's proprietary system-of-care based on high-dose administration of Cytoxan, for the prevention of graft-versus-host disease (GVHD) following bone marrow transplant.

14 Sep 2011

Jefferson's two-step bone marrow transplant procedure holds promise for cancer patients

Half-matched bone marrow or stem cell transplants for blood cancer patients have typically been associated with disappointing clinical outcomes. However, a clinical trial conducted at the Kimmel Cancer Center at Jefferson testing its unique, two-step half-match procedure has produced some promising results: the probability of overall survival was 45 percent in all patients after three years and 75 percent in patients who were in remission at the time of the transplant.

2 Sep 2011

ZIOPHARM initiates ZIN ATI-001 Phase 1 clinical study in advanced melanoma

ZIOPHARM Oncology, Inc. today announced that the first patient has been dosed in a Phase 1 clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate, in patients with advanced melanoma.

30 Aug 2011

Avastin increases tumor response rates in breast cancer patients before surgery

Amid the controversy surrounding the Food and Drug Administration's ruling that Avastin should no longer be used to treat metastatic breast cancer, a new multinational Phase III clinical trial shows that Avastin significantly increased tumor response rates in breast cancer patients when given before surgery.

24 Aug 2011